GENinCode (LON:GENI) Trading Up 9.4% – Should You Buy?

GENinCode Plc (LON:GENI)’s share price rose 9.4% during trading on Thursday . The company traded as high as GBX 0.90 and last traded at GBX 0.88. Approximately 7,631,066 shares traded hands during trading, an increase of 31% from the average session volume of 5,831,207 shares. The stock had previously closed at GBX 0.80.

GENinCode Stock Up 9.4%

The firm has a 50 day simple moving average of GBX 0.96 and a two-hundred day simple moving average of GBX 1.17. The company has a debt-to-equity ratio of 117.74, a current ratio of 0.93 and a quick ratio of 15.88. The stock has a market cap of £6.59 million, a price-to-earnings ratio of -0.42 and a beta of 0.59.

GENinCode (LON:GENI) last posted its earnings results on Monday, June 8th. The company reported GBX (2.08) earnings per share (EPS) for the quarter. The company had revenue of GBX 308 million for the quarter. GENinCode had a negative return on equity of 409.40% and a negative net margin of 185.47%. As a group, sell-side analysts expect that GENinCode Plc will post -7.1299999 EPS for the current year.

GENinCode Company Profile

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.